tbuckley/cabot-search huggingface dataset:
Abstract 326: Enhanced efficacy of Sitravatinib (MGCD516) in metastatic models of antiangiogenic therapy resistance
Authors: Melissa Dolan, Michalis Mastri, Amanda Tracz, James G. Christensen, Gurkamal Chatta, Yuhao Shi, John M. Ebos
Journal: Cancer Research (2019)

Abstract Tyrosine kinase inhibitors (TKIs) that primarily target vascular endothelial growth factor receptors (VEGFRs) are approved to treat several cancers in the metastatic setting. However, improvements in survival for most patients are short-lived and resistance is common. Sequential treatment or ‘switching’ from one VEGFR TKI to another has proven effective following failure in many instances. This may be due to broad drug-specific secondary TKI target profiles that can block metastasis- and angiogenesis-promoting processes. Here we examined sitravatinib (MGDC516), a novel small molecule TKI with activity against VEGFRs, that also can block Met, Axl, and several ephrin receptors (Eph), amongst several others. Transcriptomic and proteomic analysis showed multiple sitravatinib targets upregulated in VEGFR TKI-resistant mouse and human tumor cell lines derived from metastasis in mice. In vitro, sitravatinib treatment decreased proliferation in VEGFR TKI-resistant cells compared to untreated controls, suggesting prior RTKI resistance may enhance sitravatinib anti-tumor potency, while cabozantinib, a multi-targeted RTKI clinically approved after antiangiogenic therapy failure did not demonstrate enhanced anti-proliferative activity in resistant cells. In vivo, sitravatinib treatment significantly reduced orthotopically-implanted primary kidney and breast tumors in mice, with increased effects observed in VEGFR TKI-resistant tumors. Sitravatinib treatment was also found to suppress metastatic disease progression and improve survival in mice when continued after primary tumor removal, indicating metastasis-inhibiting effects of sitravatinib may be enhanced in VEGFR TKI-resistant settings. Together, these studies suggest that broad-spectrum RTKI inhibitors such as sitravatinib that target multiple metastasis-promoting mechanisms improve efficacy after antiangiogenic treatment failure and improve outcomes in a second-line setting. Citation Format: Melissa Dolan, Michalis Mastri, Amanda Tracz, James G. Christensen, Gurkamal Chatta, Yuhao Shi, John M. Ebos. Enhanced efficacy of Sitravatinib (MGCD516) in metastatic models of antiangiogenic therapy resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 326.
MEDU-26. LATENT SOX9-POSITIVE CELLS RESPONSIBLE FOR MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE
Authors: Sara Bolin, Vasil Savov, Anna Borgenvik, Gabriela Rosen, Alexandra Garancher, Aldwin Suryo Rahmanto, Sonja Hutter, Oliver Mainwaring, Karl Holmberg Olausson, Jessica Rusert, Anders Sundstrom, Stacey Richardson, Grammatiki Fotaki, Rebecca Hill, Adrian Dubuc, Antonia Kalushkova, Marc Remke, Matko Cancer, Helena Jernberg-Wiklund, Vijay Ramaswamy, Michael Taylor, Olle Sangfelt, Steven Clifford, Ulrich Schuller, Robert Wechsler-Reya, Holger Weishaupt, Fredrik Swartling
Journal: Neuro-Oncology (2019)

Abstract Tumor recurrence is the leading cause of death among children with medulloblastoma, the most common type of malignant pediatric brain tumors. The mechanisms behind medulloblastoma recurrence are not fully understood. We previously showed that the transcription factor SOX9 promotes cisplatin treatment resistance in medulloblastoma. Here we show that SOX9 levels correlate with poor prognosis in Group 3 tumors. By studying paired primary-recurrent medulloblastoma samples and patient-derived xenograft (PDX) models we further identified rare SOX9-positive slow-cycling, therapy-resistant tumor cells that accumulate in relapses and in leptomenigeal metastases of Group 3 and Group 4 patients. By using an inducible Tet-OFF transgenic (GTML) mouse model for malignant MYCN-driven Group 3 tumors we identified rare SOX9-positive, quiescent brain tumor cells that are more resistant to cisplatin. Dox treatment normally cures GTML transgenic animals that developed aggressive medulloblastoma by turning MYCN off. However, when crossing the Tet-OFF GTML model with a Tet-ON rtTA-Sox9 model we can redirect MYCN expression to the Sox9 promoter ultimately driving brain tumor recurrence from rare SOX9-positive cells with 100% penetrance. In this novel animal model, recurrent tumors were actively disseminating from the hindbrain to the spinal cord and into the forebrain similar to distant relapses found in patients. By overexpressing SOX9 in human Group 3 tumor cells, MYC was directly inhibited and cell proliferation was decreased. PDX models of Group 3 tumors further showed increased levels of SOX9-positivity and less proliferative cells in metastatic compartments. Expression profiling revealed that recurrences were more inflammatory, metastatic, immune evasive and showed elevated MGMT methyltransferase levels which depleted recurrent cells and sensitized them for chemotherapy when using the MGMT inhibitor lomeguatrib. To summarize, our data clarify important and complex mechanisms by which latent medulloblastoma cells fail to respond to standard therapy and generate relapses.
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies
Authors: D. Rossini, A. Sbrana, F. Bergamo, C. Manai, D. Santini, M. Ghidini, C. Antoniotti, R. Moretto, F. Marmorino, F. Urbano, M. Ronzoni, S. Noventa, G. Randon, C. Carlomagno, T. Latiano, S. Cordio, C. Granetto, C. Cremolini, A. Falcone, A. Antonuzzo
Journal: Annals of Oncology (2019)
Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals
Authors: Binod Dhakal, Smith Giri, Adam Levin, Lisa Rein, Timothy S. Fenske, Saurabh Chhabra, Nirav N. Shah, Aniko Szabo, Anita D’Souza, Marcelo Pasquini, Parameswaran Hari, Mehdi Hamadani
Journal: JAMA Network Open (2019)

Hematopoietic cell transplantation (HCT) is a therapeutic strategy in the management of several hematological cancers. Limited data exist on the incidence and predictors of 30-day readmission after HCT.To measure the incidence of and risk factors associated with 30-day readmission following HCT in the United States.This cohort study examined patient data from the US population-based Nationwide Readmissions Database. All adults (age ≥18 years) who underwent autologous (auto-) or allogenic (allo-) HCT in US hospitals between January 1, 2012, and November 30, 2014, were included. The analysis was performed from June 2018 to February 2019.The main outcome was 30-day readmission rates for auto-HCT and allo-HCT. Factors associated with readmission, including baseline demographic characteristics and disease- and hospital-related characteristics (including annual case volume), were measured.A total of 28 356 index admissions for auto-HCT in 244 centers (191 low-volume, 38 medium-volume, and 15 high-volume centers) and 17 217 index admissions for allo-HCT in 211 centers (161 low-volume, 37 medium-volume, and 13 high-volume centers) were identified during the study period. The overall 30-day readmission rates were 11.6% for auto-HCT and 24.4% for allo-HCT. The odds of readmission were significantly higher in low-volume hospitals compared with high-volume hospitals (adjusted odds ratio [aOR], 1.69; 95% CI, 1.08-2.64 for auto-HCT and aOR, 1.41; 95% CI, 1.09-1.82 for allo-HCT) but comparable to medium-volume hospitals (aOR, 1.06; 95% CI, 0.62-1.83 for auto-HCT and aOR, 1.19; 95% CI, 0.90-1.57 for allo-HCT). Other factors associated with readmission for auto-HCT included younger age (aOR for age ≥50 vs <49 years, 0.82; 95% CI, 0.68-0.98), female sex (aOR, 1.21; 95% CI, 1.06-1.36), disease type (aOR for other vs myeloma, 1.37; 95% CI, 1.06-1.77), and Elixhauser comorbidity index score (aOR for ≥20 vs 0, 1.5; 95% CI, 1.17-1.93). For allo-HCT, factors associated with readmission included disease type (aOR for acute lymphoblastic leukemia vs acute myelogenous leukemia, 1.30; 95% CI, 1.04-1.62), insurance (aOR for Medicare vs private, 1.18; 95% CI, 1.02-1.36), and Elixhauser comorbidity index score (aOR for 1-9 vs 0, 1.2; 95% CI, 1.04-1.39). Infections, neutropenic fever, and gastrointestinal symptoms were the most common reasons for readmission for both types of HCT.This study found substantial rates of readmission for both types of HCT and an inverse association between hospital HCT volume and 30-day readmission. These results may provide guidance when developing quality indicators and policies penalizing hospitals for HCT readmission.
Abstract 17483: Angiographic Outcomes of Paclitaxel Coated Balloons vs Standard Balloon Angioplasty in Peripheral Artery Disease
Authors: Arun Srinivasan Kannan, Srinivasa Madhavan, Srinath Sundararajan
Journal: Circulation (2017)

Background: The aim of this meta-analysis was to compare the angiographic outcomes in patients with femoropopliteal artery disease treated with either paclitaxel-coated balloon (PCB) or with standa...
Abstract 21348: The Difference of Antiplatelet Prescription Between Gender and the 1-Year Mortality in Patients With STEMI in Developing Country
Authors: Sowitchaya Panthong, Veraprapas Kittipibul, Paramaporn Suttirut, Vorarit Lertsuwunseri, Suphot Srimahachota, Aekarach Ariyachaipanich
Journal: Circulation (2017)

Introduction: There were inequalities in treatments prescribing to women resulted in poorer outcome in woman compare to men in many conditions include ST-elevation myocardial infarction (STEMI). Hypothesis: This study aims to described the difference of dual antiplatelet therapy (DAPT) prescription between gender and its effect on outcome. Methods: We conducted a retrospective study of consecutive patients presented with STEMI who underwent primary percutaneous coronary intervention at a tertiary care hospital in Thailand from January 2011 to December 2015. Patients’ baseline characteristics, usage of antiplatelet and mortality were collected. Chi-square and Log-rank were used to analyze. Results: Total of 755 patients (74.8% male) were included. Women were significantly older (68.1 ± 13.4 vs 57.6 ± 12.7, p &lt;0.005), had lower hemoglobin at baseline (12 ± 1.9 vs 14.3 ± 2, p &lt;0.005) and had more comorbidities include diabetes mellitus (46.6% vs 26.2%, p&lt;0.005), hypertension (76.8% vs 49.2%, P&lt;0.005) and chronic kidney disease (7.6% vs 3%, p=0.009). At the time of discharge, aspirin and clopidogrel were less commonly prescribed in women (86% vs 92.7%, p = 0.015 and 85.5% vs 91.1%, p=0.049, respectively) but the usage of DAPT was not statistically different between female and male (85.3% vs 90.9%, p=0.061) (Table). The 1-year survival is lower in women (79.5% vs 88.6%, p = 0.001). Patients who were discharged with DAPT had lower 1-year mortality than those without DAPT (2.6% vs 16.7%, p=0.003). Men, but not women, who were discharged with DAPT have the 1-year survival rate higher than those without DAPT. Conclusions: In conclusion, aspirin and clopidogrel but not DAPT were less commonly prescribed for women. The 1-year mortality was high in female which reflects the same disparity in outcomes that was found in western countries. There may be different effect of DAPT on males and female.
Abstract 4975: Using humanized B-hSIRPa/hCD47 mouse model to evaluate the efficacy and toxicity of CD47 and SIRPa antibodies
Authors: Yanan Li, Chaoshe Guo, Jie Xiang, Qingcong Lin
Journal: Cancer Research (2019)

Abstract Cancer immunotherapy is one of the most promising research areas in the field of cancer therapy. Along the IO drug development process, production of mouse models for in vivo efficacy evaluation has always been a rate-limiting step. Therefore, we generated a novel humanized knock-in mouse to evaluate the efficacy of human IO antibodies. CD47 is a transmembrane protein expressed in many human tissues. SIRPa, which is expressed on phagocytic cells, was identified as the receptor of CD47. Engagement of SIRPa by CD47 serves as “do not eat me” signal, inhibiting the phagocytic activity of macrophages. Antibodies interfering with the CD47-SIRPa interaction block inhibition and promote tumor destruction. While CD47 is a potential target for antibody development, side effects associated with CD47 blockade have emerged as a major concern, especially anemia. To evaluate the efficacy and toxicity of CD47 antibody, we generated a double humanized B-hSIRPa/hCD47 mouse. In this model, exon2 in mouse SIRPa and CD47 were replaced with the corresponding human sequences. In homozygous mice, mouse SIRPa and CD47 was absent and only human protein expression was detected, B-hSIRPa/hCD47 mice paired with genetically modified MC38-hCD47 cancer cells were used to screen CD47 antibodies by balancing their efficacy and toxicity. Antibodies with less toxicity exhibited minimal weight loss, minimal effects on blood cell and platelet production, and reduced ALT/AST elevation in mice. Thus, we demonstrated that these humanized mice could expedite and improve the development of safer CD47 antibodies. Humanized B-hSIRPa/hCD47 mice can also be used to evaluate the efficacy of antibodies targeting SIRPa. We also generated triple humanized B-hPD-1/hSIRPa/hCD47 and B-hPD-L1/hSIRPa/hCD47 mice that would be useful to develop combination therapies of PD-1/PD-L1 and SIRPa/CD47 antibodies. Humanized B-hSIRPa/hCD47 mice are a promising in vivo efficacy model for the development of CD47 and SIRPa antibodies that can be advanced to human clinical trials. Citation Format: Yanan Li, Chaoshe Guo, Jie Xiang, Qingcong Lin. Using humanized B-hSIRPa/hCD47 mouse model to evaluate the efficacy and toxicity of CD47 and SIRPa antibodies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4975.
Effect of Introducing a Default Order in the Electronic Medical Record on Unnecessary Daily Imaging During Palliative Radiotherapy for Adults With Cancer
Authors: Sonam Sharma, David Guttmann, Dylan S. Small, Charles A. L. Rareshide, Joshua Jones, Mitesh S. Patel, Justin E. Bekelman
Journal: JAMA Oncology (2019)

This randomized clinical trial examines the effect of implementing a default order option in the electronic medical record on daily imaging utilization for patients with cancer undergoing radiotherapy during palliative care.
Activity of thymidine kinase as a prognostic marker of malignant proliferation in adolescents with lymphadenopathy.
Authors: Viktoria V. Dmitrieva, Elena M. Frantsiyants, Irina B. Lysenko, Elena E. Pak, Olga V. Kozyuk, Nadezhda V. Nikolaeva, Elena A. Kapuza, Olga N. Shatokhina, Larisa Yu. Shashkina, Sergei A. Kuznetsov, Gulnara A. Mkrtchyan, Maria V. Starzhetskaya, Aleksandra I. Bespalova, Darya Yu. Yurchenko, Olga P. Popovyan, Olga Yu. Kutsevalova
Journal: Journal of Clinical Oncology (2019)

e19013 Background: Lymphadenopathy presents an important differential diagnostic problem. Thymidine kinase (TK) is an intracellular enzyme catalyzing the conversion of thymidine to thymidine monophosphate in the presence of adenosine triphosphate. TK is the product of certain genes for the progression from G1 through S phase. Determination of serum levels of the first TK isoenzyme is considered to have prognostic significance in malignant proliferation. TK increases significantly in the direct contact of malignant cells with biological fluids such as blood, lymph, or serous effusions, therefore its level changes most significantly in systemic blood diseases. Elevated serum TK has prognostic information and determines a high risk of tumor progression. The purpose of the study was to improve the accuracy of diagnosis of Hodgkin's lymphoma in adolescents, with its differentiation from lymphadenitis. Methods: The study included 34 patients: 13 – lymphadenitis, 21 – Hodgkin's lymphoma. Healthy donors served as a control group. Activity of TK1 (U/L) was determined in the blood serum by radioenzymatic method (in vitro) using a standard test system (Immunotech, BeckmanCoulter, Czech Republic). When TK1 activity was within 10.6-14.8 U/L, adenopathy of unclear etiology was considered lymphadenitis, and in 39.6-45 U/L – Hodgkin's lymphoma. Results: Activity of TK in the blood serum of patients with lymphadenitis (U/L) is shown in Table. Conclusions: Activity of thymidine kinase 1 can be measured as an objective marker for the proliferation of malignant cells, increasing the accuracy of Hodgkin's lymphoma diagnosis in adolescents.[Table: see text]
ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles
Authors: Wonhyo Seo, Yanhang Gao, Yong He, Jing Sun, Hongqin Xu, Dechun Feng, Seol Hee Park, Young-Eun Cho, Adrien Guillot, Tianyi Ren, Ruihong Wu, Jingyun Wang, Seung-Jin Kim, Seonghwan Hwang, Suthat Liangpunsakul, Yingzi Yang, Junqi Niu, Bin Gao
Journal: Journal of Hepatology (2019)
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Authors: Clara Depommier, Amandine Everard, Céline Druart, Hubert Plovier, Matthias Van Hul, Sara Vieira-Silva, Gwen Falony, Jeroen Raes, Dominique Maiter, Nathalie M. Delzenne, Marie de Barsy, Audrey Loumaye, Michel P. Hermans, Jean-Paul Thissen, Willem M. de Vos, Patrice D. Cani
Journal: Nature Medicine (2019)
Abstract 18835: Use of Coronary Artery Calcification for Prediction of Cardiovascular Death in Elderly Patients
Authors: Frances Wang, Yoav Arnson, Alan Rozanski, Matthew J Budoff, Michael D Miedema, Khurram Nasir, Leslee J Shaw, John A Rumberger, Roger S Blumenthal, Michael J Blaha, Daniel S Berman
Journal: Circulation (2017)

Introduction: Coronary artery calcium (CAC) is a robust predictor of adverse cardiovascular disease (CVD) events in the general population. The prevalence and extent of CAC are strongly correlated ...
Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)–deficient non-squamous non-small cell lung cancer.
Authors: Akhila Ganeshi Wimalasingham, Melissa Mary Phillips, Louise Lim, Sukaina Rashid, Peter Edward Hall, Ramsay Khadeir, Jeremy P. C. Steele, John Conibear, Xiaoxing Feng, Stephen Ellis, Pui Ying Chan, Jim Thomson, Amanda L. Johnston, John S. Bomalaski, Simon Pacey, Michael Sheaff, Peter Wojciech Szlosarek
Journal: Journal of Clinical Oncology (2019)

9097 Background: Pegylated arginine deiminase (ADI-PEG20) targets ASS1-ve tumors, including non–small-cell lung cancer (NSCLC), by potentiating pemetrexed cytotoxicity via arginine depletion. In Beddowes et al (JCO 2017) we showed a 100% disease control rate in thoracic cancers treated with ADI-PEG20, cisplatin and pemetrexed (ADIPemCis). Thus, we tested ADIPemCis in a phase I dose-expansion cohort study of patients (pts) with non-squamous NSCLC. Methods: Good performance (ECOG 0-1) advanced non-squamous NSCLC pts were enrolled at the maximum tolerated dose (MTD) of ADIPemCis, using tumoral ASS1 loss as a selection biomarker. Pem (500mg/m2) and Cis (75mg/m2) were given every 3 weeks with weekly IM ADI-PEG20 (36mg/m2) for up to 4 cycles with maintenance ADI-PEG20 or Pem in responding pts. Primary endpoint was tumor response rate (RR by RECIST 1.1), with secondary endpoints including progression-free survival (PFS), overall survival (OS), and toxicity. We also measured plasma [arginine] and [citrulline], anti-ADI-PEG20 antibodies, and PD-L1 expression. Results: 21 of 70 screened pts (median age 60.1) were enrolled between April 15 and August 17. A confirmed partial response (PR) was observed in 55.6 % (n = 10/18 evaluable pts). Median PFS and OS were 4 months (95% CI 2.9-4.8) and 7.2 months (95% CI 5.1-18.4), respectively. 9% (n = 2/21) remain alive on subsequent therapies. 43% (n = 9/21) experienced grade 3/4 treatment-related toxicities, commonly non-febrile neutropenia. Plasma [arginine] declined rapidly and [citrulline] increased; both changes persisted at 16 weeks. 55% of pts’ tumors (n = 6/11 ) were PD-L1 &lt; 1% by immunohistochemistry. Conclusions: The ADIPemCis regimen is active and safe in ASS1-ve NSCLC pts almost doubling the expected RR. However, the short survival compared with ASS1-agnostic historical controls indicates that ASS1 (and frequent PD-L1) loss selects for a biologically more aggressive and immunorefractory NSCLC phenotype. The iTRAP study opening Q2 of 2019 will assess the safety and tolerability of ADIPemPlatinum(Carbo) with atezolizumab in pts with ASS1-deficient non-squamous NSCLC. Clinical trial information: NCT02029690.
Abstract 3834: Epigenetic modification of oncogenes or tumor suppressor genes by thymoquinone in triple negative breast cancer
Authors: Md. Asaduzzaman Khan, Meiling Zheng, Junjiang Fu
Journal: Cancer Research (2019)

Abstract Background and Objective: Triple negative breast cancer (TNBC) is a molecular subtype, and most aggressive and deadly among breast cancers. Different molecular subtypes of breast cancer have distinct molecular mechanisms, and in case of TNBC, the mechanisms are complex, and still obscure. Development of therapeutic strategies are thus also difficult against TNBC. Thymoquinone (TQ) is a natural compound, which has been found effective against TNBC cells, but the mechanism of TQ action in TNBC is not clear. In this study, we have focused on TQ’s genome-wide epigenetic effect on TNBC cell line BT549. Methods: The BT549 cells were treated with 1-10 µM of TQ for cellular growth analysis, and isolated DNA for dot blot analysis with anti-5-methyl cytosine (anti-5MC) antibody to observe whole genome methylation status affected by TQ. Also the chromatin immunoprecipitation (ChIP) was performed with anti-methyl binding domain protein (anti-MBD1) to identify DNA sections, of which methylation status is changed by TQ. Results: Cell viability assay showed that TQ dose-dependently reduced BT549 cell growth. DNA dot blot analysis results indicated no obvious changes in total methylation status change in genomic DNA. However, ChIP-seq confirmed that methylation level was affected (either increased or decreased) in certain genomic locations by TQ treatment. Some of the locations are proximal or close to some genes, indicating that this epigenetic modification might have influence on these genes’ expression pattern. Conclusion: Thus, here in this preliminary research study, we indicate some genes, which might be epigenetically targeted by TQ in TNBC cells. Funding support: National Natural Science Foundation of China (Grant No. 81850410555, 81672887, 81172049) Citation Format: Md. Asaduzzaman Khan, Meiling Zheng, Junjiang Fu. Epigenetic modification of oncogenes or tumor suppressor genes by thymoquinone in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3834.
Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1β inhibition
Authors: Yael Gernez, Adriana A. de Jesus, Hanouf Alsaleem, Claudia Macaubas, Amitava Roy, Daniel Lovell, Karthik A. Jagadeesh, Sara Alehashemi, Laura Erdman, Michael Grimley, Susanna Talarico, Rosa Bacchetta, David B. Lewis, Scott W. Canna, Ron M. Laxer, Elizabeth D. Mellins, Raphaela Goldbach-Mansky, Katja G. Weinacht
Journal: Journal of Allergy and Clinical Immunology (2019)
Abstract 15046: Apical Rocking Predicts Response to Cardiac Resynchronization Therapy - A Novel Application of Rotational Strain Analysis
Authors: Satya Rao, Thomas H Hauser, Kalon K Ho, Warren J Manning, Ian McCormick, James D Chang
Journal: Circulation (2012)

Introduction One third of patients who receive cardiac resynchronization therapy (CRT) in accordance with current guidelines fail to benefit from this therapy. A threshold level of contractile func...